CBChristopher L. Brummel

Christopher L. Brummel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher L. Brummel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Brian Boucher

    Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Inc. 130 Waverly Street Cambridge MA 02139 USA

    1 shared publication
  • Hong Gao

    Drug Innovation Pharmacokinetics, Vertex Pharmaceuticals Inc., Cambridge, MA02139, USA

    1 shared publication
  • Hong Tsao

    Drug Innovation Pharmacokinetics, Vertex Pharmaceuticals Inc., Cambridge, MA02139, USA

    1 shared publication
  • Nigel P. Ewing

    Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Inc. 130 Waverly Street Cambridge MA 02139 USA

    1 shared publication
  • Olivier Materne

    Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Inc. 130 Waverly Street Cambridge MA 02139 USA

    1 shared publication
  • Shengkai Liao

    Department of Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Inc. 130 Waverly Street, Cambridge, MA 02139, USA

    1 shared publication

Latest Publications

  • High‐throughput screening for glutathione conjugates using stable‐isotope labeling and negative electrospray ionization precursor‐ion mass spectrometry

    by Shengkai Liao, Nigel P. Ewing, Brian Boucher, Olivier Materne, Christopher L. Brummel

    RATIONALE: It has been proposed that the increase in the instances of idiosyncratic adverse drug reactions (IADRs) and black box warnings may be attributed to the occurrence of reactive metabolites. Consequently, a high‐throughput screen for reactive metabolites formed from liver microsome extracts with added glutathione (GSH) was developed for use in the early stages of drug discovery. METHODS: To enhance sensitivity and specificity, as well as accelerate data processing, a mixture of a stable‐isotope probe consisting of natural GSH (light GSH) and stable‐isotope‐labeled [ 15 N, 13 C 2 ] GSH (heavy GSH) at a ratio of 1:1 was used. Any metabolite that reacted with the GSH results in the formation of light and heavy GSH conjugates with a 3 Da difference. Employing a precursor‐ion scan using negative ion electrospray ionization (ESI) corresponding to the expected fragments, signals with the appropriate ratio in the precursor ion scan are then further examined. RESULTS: The new method greatly simplifies data collection by assuming molecules containing GSH will fragment to form specific ions. As such, this approach accelerates data processing (and collection) at the risk of missing compounds that do not fragment as expected. The assay was validated with 33 diverse drugs known to form GSH conjugates, 5 drugs known to not form GSH adducts and over 100 samples containing components of the normal in vitro matrix. In all cases data collected matched the expected result. CONCLUSIONS: The observed sensitivity, specificity, and fast data processing make this assay an excellent fit for high‐throughput screening of reactive metabolites in the early stages of drug discovery. This method is not intended to eliminate compounds or terminate their development. Instead, it is to bring forward molecules with one less liability and thus a greater probability of ultimate success. Copyright © 2012 John Wiley & Sons, Ltd.


  • Minimizing Matrix Effects While Preserving Throughput in LC–MS/MS Bioanalysis

    by Zhengqi Ye, Hong Tsao, Hong Gao, Christopher L Brummel

    Background: Phospholipids are known to cause matrix effects in LC–MS analysis and are not effectively removed by one of the most common method of sample preparation: organic solvent protein precipitation. The objective of this research is to minimize phospholipid interferences chromatographically. Results: In this article we examine several chromatographic approaches and highlight the method we developed that allows for the rapid gradient separation of model drug molecules from phospholipids. Conclusion: The new approach (which utilizes a mixture of methanol and acetonitrile as the organic mobile phase on a 2.1 × 20 mm C18 column) minimized phospholipids-related matrix effects in the analysis of plasma samples prepared by protein precipitation and is suitable for high-throughput bioanalysis in drug discovery.